Baxter’s Generic Anesthetic Prevails In Patent Dispute With Abbott Labs
Abbott sued Baxter in March 2001, when the generic maker sought approval to manufacture sevoflurane, the active ingredient in Ultane. Baxter completed an Abbreviated New Drug Application with the U.S. Food and Drug Administration, declaring it was not infringing Abbott’s patent.
A year later, the U.S. District Court for the Northern District of Illinois...
To view the full article, register now.